NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.

[1]  J. Falkenburg,et al.  Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro. , 2010, Blood.

[2]  A. Toubert,et al.  MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease. , 2009, Blood.

[3]  R. Storb,et al.  The role of B cells in the pathogenesis of graft-versus-host disease. , 2009, Blood.

[4]  D. Munn,et al.  Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. , 2009, Blood.

[5]  Yun Ji,et al.  Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity , 2009, Proceedings of the National Academy of Sciences.

[6]  V. Bronte.  Myeloid‐derived suppressor cells in inflammation: Uncovering cell subsets with enhanced immunosuppressive functions , 2009, European journal of immunology.

[7]  S. Riddell,et al.  Safety and immunologic effects of IL-15 administration in nonhuman primates. , 2009, Blood.

[8]  J. Kutok,et al.  Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation , 2009, Proceedings of the National Academy of Sciences.

[9]  M. Heemskerk,et al.  Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients. , 2009, Blood.

[10]  B. Djulbegovic,et al.  Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  G. Dotti.  Blocking PD-1 in cancer immunotherapy. , 2009, Blood.

[12]  B. Baban,et al.  IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells1 , 2009, The Journal of Immunology.

[13]  R. Storb,et al.  Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia , 2009, Clinical Cancer Research.

[14]  M. Berg,et al.  Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. , 2009, Cytotherapy.

[15]  N. Wentzensen,et al.  A systematic review of humoral immune responses against tumor antigens , 2009, Cancer Immunology, Immunotherapy.

[16]  D. Jain,et al.  Central Memory CD8+ T Cells Induce Graft-versus-Host Disease and Mediate Graft-versus-Leukemia1 , 2009, The Journal of Immunology.

[17]  D. Campana,et al.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.

[18]  J. Ritz,et al.  Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. , 2009, Blood.

[19]  É. Vivier,et al.  NK Cell Responsiveness Is Tuned Commensurate with the Number of Inhibitory Receptors for Self-MHC Class I: The Rheostat Model 1 , 2009, The Journal of Immunology.

[20]  P. Brodin,et al.  NK cell education: not an on-off switch but a tunable rheostat. , 2009, Trends in immunology.

[21]  S. Ogawa,et al.  HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. , 2009, Blood.

[22]  C. Divino,et al.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.

[23]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[24]  M. Atkins,et al.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. , 2009, Cancer research.

[25]  L. Hennighausen,et al.  Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells , 2009, Nature Immunology.

[26]  K. Keyvanfar,et al.  Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. , 2009, Blood.

[27]  J. D. Di Santo,et al.  IL-15 trans-presentation promotes human NK cell development and differentiation in vivo , 2009, The Journal of experimental medicine.

[28]  Peter Parham,et al.  Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. , 2009, Blood.

[29]  Joseph C. Sun,et al.  Adaptive Immune Features of Natural Killer Cells , 2009, Nature.

[30]  Xuetao Cao,et al.  Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β11 , 2009, The Journal of Immunology.

[31]  H. Togari,et al.  HapMap scanning of novel human minor histocompatibility antigens. , 2008, Blood.

[32]  S. Kaech,et al.  Intrinsic and extrinsic control of effector T cell survival and memory T cell development , 2009, Immunologic research.

[33]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[34]  J. Falkenburg,et al.  Identification of four new HLA-DR restricted minor histocompatibility antigens as hematopoietic targets in anti-tumor immunity , 2009 .

[35]  H. Kolb.  Graft-versus-leukemia effects of transplantation and donor lymphocytes. , 2008, Blood.

[36]  R. Brand,et al.  Female‐Versus‐Male Alloreactivity as a Model for Minor Histocompatibility Antigens in Hematopoietic Stem Cell Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  D. Venzon,et al.  Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets , 2008, The Journal of experimental medicine.

[38]  J. Falkenburg,et al.  HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia , 2008, Leukemia.

[39]  W. Leonard,et al.  IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. , 2008, Blood.

[40]  Jeffrey K. Mito,et al.  DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. , 2008, Blood.

[41]  P. Rodriguez,et al.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives , 2008, Immunological reviews.

[42]  V. Bronte,et al.  Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.

[43]  D. Jain,et al.  CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. , 2008, Blood.

[44]  W. Leonard,et al.  Interleukin-21: basic biology and implications for cancer and autoimmunity. , 2008, Annual review of immunology.

[45]  J. Falkenburg,et al.  Identification of phosphatidylinositol 4-kinase type II β as HLA class II-restricted target in graft versus leukemia reactivity , 2008, Proceedings of the National Academy of Sciences.

[46]  D. Jain,et al.  Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. , 2008, Blood.

[47]  D. Munn,et al.  Creating immune privilege: active local suppression that benefits friends, but protects foes , 2008, Nature Reviews Immunology.

[48]  D. Neuberg,et al.  MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma , 2008, Proceedings of the National Academy of Sciences.

[49]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[50]  A. Begovich,et al.  The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. , 2007, Blood.

[51]  R. Willemze,et al.  Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning , 2007, Leukemia.

[52]  D. Munn,et al.  The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation. , 2007 .

[53]  J. Ritz,et al.  High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease , 2007, Clinical Cancer Research.

[54]  Marcela R. Uribe,et al.  Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia , 2007, Leukemia.

[55]  E. Wherry,et al.  Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. , 2007, Immunity.

[56]  D. Douek,et al.  Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. , 2007, Blood.

[57]  R. Fanin,et al.  Treatment of refractory chronic GVHD with rituximab: a GITMO study , 2007, Bone Marrow Transplantation.

[58]  S. Ogawa,et al.  Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. , 2007, Blood.

[59]  Michael Y. Gerner,et al.  Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor1 , 2007, The Journal of Immunology.

[60]  T. Naoe,et al.  A Single Minor Histocompatibility Antigen Encoded by UGT2B17 and Presented by Human Leukocyte Antigen-A*2902 and -B*4403 , 2007, Transplantation.

[61]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[62]  P. Sinha,et al.  Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. , 2007, Cancer research.

[63]  M. Kester,et al.  Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. , 2007, Blood.

[64]  M. Prlic,et al.  Rapid generation of a functional NK-cell compartment. , 2007, Blood.

[65]  M. Baccarani,et al.  Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. , 2007, Blood.

[66]  J. Weiss,et al.  IFN-γ mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy , 2007, Nature Medicine.

[67]  S. Rosenberg,et al.  Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. , 2007, The Journal of clinical investigation.

[68]  A. Thomas,et al.  Natalizumab Therapy for Moderate to Severe Crohn Disease in Adolescents , 2007, Journal of pediatric gastroenterology and nutrition.

[69]  C. Bokemeyer,et al.  Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. , 2007, Blood.

[70]  R. Kozarek,et al.  Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab , 2007, Inflammatory bowel diseases.

[71]  M. Martelli,et al.  Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. , 2006, Blood.

[72]  S. Gasser,et al.  Activation and self‐tolerance of natural killer cells , 2006, Immunological reviews.

[73]  Lieping Chen,et al.  Mechanisms of GVL Against a Murine Blast Crisis CML. , 2006 .

[74]  N. Kröger,et al.  Low Number of Donor Activating Killer Immunoglobulin-Like Receptors (KIR) Genes but not KIR-Ligand Mismatch Prevents Relapse and Improves Disease-Free Survival in Leukemia Patients After In Vivo T-Cell Depleted Unrelated Stem Cell Transplantation , 2006, Transplantation.

[75]  S. Welte,et al.  Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction , 2006, Nature Immunology.

[76]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[77]  M. Caligiuri,et al.  The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[78]  D. Middleton,et al.  Human NK cell education by inhibitory receptors for MHC class I. , 2006, Immunity.

[79]  J. Ritz,et al.  Rituximab for steroid-refractory chronic graft-versus-host disease. , 2006, Blood.

[80]  J. Sprent,et al.  Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes , 2006, Science.

[81]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[82]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[83]  M. V. D. van den Brink,et al.  Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. , 2006, Blood.

[84]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[85]  Chen Dong,et al.  Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. , 2006, Journal of immunology.

[86]  J. Falkenburg,et al.  Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice , 2006, Leukemia.

[87]  M. Kester,et al.  Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. , 2005, Blood.

[88]  Yao-Tseng Chen,et al.  NY-ESO-1: review of an immunogenic tumor antigen. , 2006, Advances in cancer research.

[89]  A. Thomson,et al.  Activated T Cells Resting Regulatory T Cells from + CD25+ CD4 Programmed Cell Death-1 Discriminates Regulated Compartmentalization of , 2006 .

[90]  B. Comin-Anduix,et al.  Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  M. Leppert,et al.  A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. , 2005, The Journal of clinical investigation.

[92]  K. Rezvani,et al.  The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. , 2005, Blood.

[93]  R. Korngold,et al.  A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses , 2005, Nature Medicine.

[94]  M. V. D. van den Brink,et al.  Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. , 2005, Blood.

[95]  M. V. D. van den Brink,et al.  CCR2 is required for CD8-induced graft-versus-host disease. , 2005, Blood.

[96]  J. Curtsinger,et al.  Signal 3 Tolerant CD8 T Cells Degranulate in Response to Antigen but Lack Granzyme B to Mediate Cytolysis1 , 2005, The Journal of Immunology.

[97]  L. Lybarger,et al.  Licensing of natural killer cells by host major histocompatibility complex class I molecules , 2005, Nature.

[98]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[99]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[100]  M. Huang,et al.  Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. , 2005, Cancer research.

[101]  J. Serody,et al.  Leukocyte migration and graft-versus-host disease. , 2005, Blood.

[102]  Bingyan Wu,et al.  Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. , 2005, Blood.

[103]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[104]  A. Rudensky,et al.  Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). , 2005, Blood.

[105]  A. Elmaagacli,et al.  Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. , 2005, Blood.

[106]  R. Flavell,et al.  Toll-like receptor 3 promotes cross-priming to virus-infected cells , 2005, Nature.

[107]  M. Mescher,et al.  Cutting Edge: Bcl-3 Up-Regulation by Signal 3 Cytokine (IL-12) Prolongs Survival of Antigen-Activated CD8 T Cells1 , 2005, The Journal of Immunology.

[108]  D. Jain,et al.  Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. , 2004, Blood.

[109]  Catherine J. Wu,et al.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. , 2004, Blood.

[110]  J. Falkenburg,et al.  Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFNγ-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion , 2005, Leukemia.

[111]  C. Harding,et al.  Type I IFN and Stabilization of Class I MHC Cross-Presentation by CpG DNA Involves Enhancement of Dendritic Cell Antigen , 2005 .

[112]  L. Moretta,et al.  Killer immunoglobulin-like receptors. , 2004, Current opinion in immunology.

[113]  K. Kuzushima,et al.  Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versus-leukemia response , 2004, Bone Marrow Transplantation.

[114]  A. Hagenbeek,et al.  Prevalence and clinical significance of resistance to perforin- and FAS-mediated cell death in leukemia , 2004, Leukemia.

[115]  P. Pandolfi,et al.  GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-Versus-Host Disease , 2004, The Journal of experimental medicine.

[116]  P. Cresswell,et al.  Cellular mechanisms governing cross-presentation of exogenous antigens , 2004, Nature Immunology.

[117]  W. Pear,et al.  Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. , 2004, Blood.

[118]  G. Belz,et al.  Cross‐presentation, dendritic cell subsets, and the generation of immunity to cellular antigens , 2004, Immunological reviews.

[119]  J. Ritz,et al.  Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation , 2004, The Journal of experimental medicine.

[120]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[121]  F. Christiansen,et al.  The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. , 2004, Tissue antigens.

[122]  N. Chao,et al.  Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. , 2004, Blood.

[123]  A. Greenberg,et al.  LPAM (α4β7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease , 2004 .

[124]  Catherine J. Wu,et al.  Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. , 2004, Blood.

[125]  M. V. D. van den Brink,et al.  LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. , 2004, Blood.

[126]  F. Appelbaum,et al.  Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. , 2004, Blood.

[127]  Stephen C. Jones,et al.  Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model. , 2003, The Journal of clinical investigation.

[128]  M. Bevan,et al.  B7h is required for T cell activation, differentiation, and effector function , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[129]  D. Douek,et al.  Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. , 2003, Blood.

[130]  P. Borrow,et al.  Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon , 2003, Nature Immunology.

[131]  A. Panoskaltsis-Mortari,et al.  Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1 , 2003, The Journal of Immunology.

[132]  Franco Locatelli,et al.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. , 2003, Blood.

[133]  J. Ritz,et al.  Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. , 2003, Cancer research.

[134]  J. Curtsinger,et al.  Signal 3 Determines Tolerance versus Full Activation of Naive CD8 T Cells , 2003, The Journal of experimental medicine.

[135]  A. Sharpe,et al.  Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. , 2003, Blood.

[136]  M. Bevan,et al.  Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help , 2003, Science.

[137]  Els Goulmy,et al.  Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[138]  C. Perreault,et al.  Tissue distribution of target antigen has a decisive influence on the outcome of adoptive cancer immunotherapy. , 2003, Blood.

[139]  村田 誠.  A human minor histocompatibility antigen resulting from differential expression due to a gene deletion , 2003 .

[140]  S. Malarkannan,et al.  Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. , 2002, Blood.

[141]  Daniel J Weisdorf,et al.  Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. , 2002, Blood.

[142]  P. Kantoff,et al.  CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. , 2002, Cancer research.

[143]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[144]  Michael Loran Dustin,et al.  The immunological synapse: integrins take the stage , 2002, Immunological reviews.

[145]  A. Theofilopoulos,et al.  T cell homeostatic proliferation elicits effective antitumor autoimmunity. , 2002, The Journal of clinical investigation.

[146]  J. Ritz,et al.  Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[147]  Catherine J. Wu,et al.  Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. , 2002, Blood.

[148]  J. Massagué,et al.  Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. , 2002, Blood.

[149]  J. Drijfhout,et al.  The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. , 2002, Blood.

[150]  S. Burakoff,et al.  Cytolytic pathways in haematopoietic stem-cell transplantation , 2002, Nature Reviews Immunology.

[151]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.

[152]  J. Mulé,et al.  Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[153]  H. Hashimoto,et al.  Preferential Blockade of CD8+ T Cell Responses by Administration of Anti-CD137 Ligand Monoclonal Antibody Results in Differential Effect on Development of Murine Acute and Chronic Graft-Versus-Host Diseases1 , 2001, The Journal of Immunology.

[154]  J. Peschon,et al.  Ligation of 4-1BB (CDw137) Regulates Graft-Versus-Host Disease, Graft-Versus-Leukemia, and Graft Rejection in Allogeneic Bone Marrow Transplant Recipients1 , 2001, The Journal of Immunology.

[155]  J. Allison,et al.  ICOS co-stimulatory receptor is essential for T-cell activation and function , 2001, Nature.

[156]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[157]  D. Neuberg,et al.  Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[158]  R. Korngold,et al.  Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. , 2000, Blood.

[159]  C. Anasetti,et al.  CD28-Specific Antibody Prevents Graft-Versus-Host Disease in Mice1 , 2000, The Journal of Immunology.

[160]  H. Pircher,et al.  Distinct migration patterns of naive and effector CD8 T cells in the spleen: correlation with CCR7 receptor expression and chemokine reactivity , 1999, European journal of immunology.

[161]  J. Crawford,et al.  Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia , 1999 .

[162]  J. Dick,et al.  CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[163]  A. Tosti,et al.  Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.

[164]  R. Flavell,et al.  Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. , 1999, Journal of immunology.

[165]  直子 加藤,et al.  Graft-Versus-host Disease , 1999 .

[166]  J. Dick,et al.  CD 8 1 minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells , 1999 .

[167]  J. Crawford,et al.  Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. , 1999, The Journal of clinical investigation.

[168]  Lieping Chen,et al.  NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. , 1998, Cellular immunology.

[169]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.

[170]  H. Hashimoto,et al.  Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. , 1998, Journal of immunology.

[171]  J. Cyster,et al.  A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[172]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.

[173]  C. Kurts,et al.  CD4+ T Cell Help Impairs CD8+ T Cell Deletion Induced by Cross-presentation of Self-Antigens and Favors Autoimmunity , 1997, The Journal of experimental medicine.

[174]  A. Barrett,et al.  Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. , 1997, Blood.

[175]  D. Neuberg,et al.  Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. , 1997, The Journal of clinical investigation.

[176]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[177]  R. Flavell,et al.  Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. , 1997, Journal of immunology.

[178]  K. Parker,et al.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.

[179]  E. Podack,et al.  The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice , 1996, The Journal of experimental medicine.

[180]  J. Falkenburg,et al.  Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. , 1995, The Journal of clinical investigation.

[181]  S. Steinberg,et al.  Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. , 1995, The New England journal of medicine.

[182]  E. Butcher,et al.  Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. , 1994, Journal of immunology.

[183]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[184]  D. Longo,et al.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.

[185]  J. Falkenburg,et al.  Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes , 1991, The Journal of experimental medicine.

[186]  S. Weissman,et al.  cDNA sequences of two inducible T-cell genes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[187]  M. Sykes.  Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors , 2022 .